GlassScriptPhysician profile
Rajesh Raina
NPI 1205934437
$4,380.74
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,139 · 2020: $86.04 · 2021: $135 · 2022: $21.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaneka Medical America LLC | $3,658.94 | 2019 | |
| Welch Allyn | $355.82 | 2019 | |
| Allergan, INC. | $178.93 | 2019-2020 | |
| Abbvie INC. | $88.49 | 2021 | |
| Esperion Therapeutics, INC. | $24.44 | 2021 | |
| Abbott Laboratories | $21.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.12 | 2022 | |
| Lilly USA, LLC | $16.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.